Citation:

Rajesh Munirathnam, 2022. "Precision Medicine in Oncology: How Data Science is Revolutionizing Cancer Treatment", ESP Journal of Engineering & Technology Advancements 2(2): 114-124.

Abstract:

Data science is revolutionizing oncology by shifting towards precision medicine. Given the availability of enormous volumes of data such as genomics, clinic history, and patient outcome, data driven approach provides the best opportunity for effective cancer treatment. Advanced methods of data analysis, such as machine learning including artificial intelligence, are also helping in the discovery of new biomarkers, prognosis of treatment outcomes and learning of therapeutic regimens. In cancer treatment, the use of data science and the discovery of data science is perhaps one of the most fascinating developments in the pharmaceutical industry in the past decade, especially in the case of cancer research, where efforts are geared towards designing personalized treatment for patients. Addressing major technologies, including big data and analytics, AI as well as bioinformatics we contemplate their role in enhancing the diagnosis quality, patients’ prognosis and prospective drug discovery. In the same manner, opportunities such as data privacy, data integration across multiple heterogenic databases, and fair distribution of Precision therapies are discussed. In this paper, based on the examples of cases and the development trends, the role and the prospect of data science in oncology are introduced to the readers.

References:

[1] Brant, J. M., & Mayer, D. K. (2017). Precision Medicine: Accelerating the science to revolutionize cancer care. Clinical Journal of Oncology Nursing, 21(6).

[2] Zucman-Rossi, J., Villanueva, A., Nault, J. C., & Llovet, J. M. (2015). Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology, 149(5), 1226-1239.

[3] Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England journal of medicine, 372(9), 793-795.

[4] Patel, A., & Bernicker, E. H. (2018). Targeted Therapies for Lung Cancer. Precision Molecular Pathology of Lung Cancer, 239-255.

[5] Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015). Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 15(12), 747-756.

[6] Woodhouse, Ryan, et al. "Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin." PloS one 15.9 (2020): e0237802.

[7] Redig, A. J., & Jänne, P. A. (2015). Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol, 33(9), 975-977.

[8] Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: from science to value. Health Affairs, 37(5), 694-701.

[9] Mardis, E. R. (2019). The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harbor Perspectives in Medicine, 9(9), a036269.

[10] Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., ... & Yarmush, M. L. (2018). The growing role of precision and personalized medicine for cancer treatment. Technology, 6(03n04), 79-100.

[11] Fröhlich, H., Balling, R., Beerenwinkel, N., Kohlbacher, O., Kumar, S., Lengauer, T., ... & Zupan, B. (2018). From hype to reality: data science enabling personalized medicine. BMC Medicine, 16, 1-15.

[12] Simonds, N. I., Khoury, M. J., Schully, S. D., Armstrong, K., Cohn, W. F., Fenstermacher, D. A., ... & Freedman, A. N. (2013). Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. Journal of the National Cancer Institute, 105(13), 929-936.

[13] Ahmed, A. A., Vundamati, D. S., Farooqi, M. S., & Guest, E. (2018). Precision medicine in pediatric cancer: current applications and future prospects. High-throughput, 7(4), 39.

[14] Nagasaka, M., & Gadgeel, S. M. (2018). Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert review of anticancer therapy, 18(1), 63-70.

[15] Reis, H., Metzenmacher, M., Goetz, M., Savvidou, N., Darwiche, K., Aigner, C., ... & Wiesweg, M. (2018). MET expression in advanced non–small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clinical lung cancer, 19(4), e441-e463.

[16] Multi-omics data integration. Multi-omics combines data from multiple platforms, 2020. online. https://www.researchgate.net/figure/Multi-omics-data-integration-Multi-omics-combines-data-from-multiple-platforms-for_fig2_346102812

[17] Gadgeel, S. M. (2017). Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Am Soc Clin Oncol Educ Book, 37, 630-639.

[18] Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.

[19] Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017). Network-based machine learning and graph theory algorithms for precision oncology. NPJ precision oncology, 1(1), 25.

[20] Heo, Y. J., Hwa, C., Lee, G. H., Park, J. M., & An, J. Y. (2021). Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Molecules and cells, 44(7), 433-443.

Keywords:

Precision Medicine, Oncology, Data Science, Cancer Treatment, Machine Learning, Artificial Intelligence, Genomics, Biomarkers, Big Data, Bioinformatics.